Watch experts decode 'The rise of ESG investing' on October 29 at 4pm. Register Now!
you are here: HomeNewsTrendsHealth
Last Updated : Oct 02, 2020 04:45 PM IST | Source: PTI

Reliance Life Sciences develops RT-PCR kit that can give COVID-19 results in 2 hours

This kit is a complete indigenous development by the R&D scientists working at the firm, they said, adding one biggest advantage of this kit is that it is simple to use and uses readily available simple reagents and primers which can be synthesised in India.

Representative image (AP Photo/Rajesh Kumar Singh)
Representative image (AP Photo/Rajesh Kumar Singh)
  • bselive
  • nselive
Todays L/H

Reliance Life Sciences has developed an RT-PCR kit that promises diagnosis of COVID-19 infection in about 2 hours, company sources said. At present, COVID-19 RT-PCR test, which is a real-time reverse transcription-polymerase chain reaction (rRT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2, takes up to 24 hours to give a diagnosis.

The sources said computational biologists at Reliance Life Sciences, a subsidiary of billionaire Mukesh Ambani-run Reliance Industries Ltd, analysed more than 100 genomes of SARS-CoV-2 sequenced in India and designed unique RT-PCR primers for developing quantitative-Real Time PCR (RT-PCR) kit for COVID-19 detection. RT-PCR kit is so far considered as Gold standard.

The kit, developed by scientists at Reliance Life Sciences, is named R-Green Kit (SARS COV2-real-time PCR) and has been technically validated by ICMR for satisfactory performance, the sources said. ICMR's validation process does not approve/disapprove the kit design as well as it does not certify user-friendliness.


The sources said the kit can detect the presence of E-gene, R-gene, RdRp gene of SARS COV2 virus with Actin as an internal control. As per ICMR results, the kit shows 98.7 percent sensitivity and 98.8 percent specificity.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

This kit is a complete indigenous development by the R&D scientists working at the firm, they said, adding one biggest advantage of this kit is that it is simple to use and uses readily available simple reagents and primers which can be synthesised in India. The diagnosis time is approximately 2 hours, they added.

A separate study by Reliance Life Sciences has indicated that the death rate for COVID-19 pandemic may significantly reduce by the end of 2020. The study showed mutation occurrence of structural and non-structural proteins of SARS-CoV-2 form more than 7,000 genome sequences of SARS-CoV-2 virus from 49 countries.

Statistical analysis showed an inverse correlation between the mutation rates of two proteins NSP6 and Surface glycoprotein (S) with the death rate, according to the study published in the Scientific Journal of Biology. It has been predicted that mutations of these two proteins will grow constantly, while the death rate would drop below 0.5 percent by end of 2020 in cluster I countries (India and Bangladesh).

In the study, it has been observed that the cluster II country (USA) mutation rate of NSP6 and S proteins are lower than cluster I and cluster III (Australia and NZ) countries. Therefore, it has been proposed that in cluster II country the death rate of COVID-19 pandemic will weaken later than cluster I and III countries, the study says.

Reliance also got a US patent for genetically modified microalgae that is said to defend/delay death. The United States Patent on September 8 issued the patent.

Follow our full coverage of the coronavirus pandemic here.

Disclaimer: “Reliance Industries Ltd. is the sole beneficiary of Independent Media Trust which controls Network18 Media & Investments Ltd.”
First Published on Oct 2, 2020 04:43 pm